SCHEMBL16620540

SCHEMBL16620540

O=C(O)CN(CC(=O)O)C(=O)CCCCC(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
MAPK1 P28482 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ALOX5 P09917 3/20 0.49
LMNA P02545 1/20 0.47
HTT P42858 1/20 0.46
CASP1 P29466 1/20 0.45
EPHX2 P34913 1/20 0.44
KDM4A O75164 1/20 0.44
KDM5A P29375 1/20 0.44
KDM4C Q9H3R0 1/20 0.44
PHF8 Q9UPP1 1/20 0.44
KDM2A Q9Y2K7 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
MAPT P10636 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A3 Q01959 1/20 0.44
KMT2A Q03164 1/20 0.44
LPAR1 Q92633 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16620860 0.88 KDM4A (0.52) ALDH1A1MAPK1L3MBTL1ALOX5LMNA
SCHEMBL18673 0.85 ALDH1A1 (0.68) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL16620634 0.84 ALOX5 (0.49) ALDH1A1MAPK1L3MBTL1ALOX5LMNA
SCHEMBL18674 0.84 ALDH1A1 (0.61) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL16620311 0.84 ALOX5 (0.46) ALDH1A1MAPK1L3MBTL1ALOX5LMNA
SCHEMBL4941879 0.84 ALDH1A1 (0.66) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL118235 0.84 ALDH1A1 (0.66) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL20624816 0.84 ALDH1A1 (0.66) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL28600680 0.84 ALDH1A1 (0.66) ALDH1A1MAPK1L3MBTL1LMNAHTT
SCHEMBL2926392 0.84 ALDH1A1 (0.66) ALDH1A1MAPK1L3MBTL1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240424109-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2024-12-26 US disclosed
EP-4436610-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme LLC (US) 2024-10-02 EP disclosed
WO-2023091441-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME LLC (US) 2023-05-25 WO disclosed
US-11041009-B2 Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes MERCK SHARP & DOHME CORP. (US) 2021-06-22 US disclosed
EP-3052134-B1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME (US) 2021-05-05 EP disclosed
US-20200087375-A1 GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME CORP. (US) 2020-03-19 US disclosed
EP-3600381-A1 GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES Merck Sharp & Dohme Corp. (US) 2020-02-05 EP disclosed
CN-105792852-B Glucose-responsive insulin conjugates 默沙东公司 2019-12-10 CN disclosed
WO-2018175272-A1 GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES MERCK SHARP & DOHME CORP. (US) 2018-09-27 WO disclosed
US-20180110863-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2018-04-26 US disclosed
EP-3280450-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES Merck Sharp & Dohme Corp. (US) 2018-02-14 EP disclosed
US-9889205-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME CORP. (US) 2018-02-13 US disclosed
US-9884125-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME CORP. (US) 2018-02-06 US disclosed
US-20160303244-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2016-10-20 US disclosed
WO-2016164288-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2016-10-13 WO disclosed
US-20160251407-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2016-09-01 US disclosed
US-9427475-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME CORP. (US) 2016-08-30 US disclosed
EP-3052134-A2 GLUCOSE-RESPONSIVE INSULIN CONJUGATES Merck Sharp & Dohme Corp. (US) 2016-08-10 EP disclosed
US-20150105317-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME LLC 2015-04-16 US disclosed
WO-2015051052-A2 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180110863-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 ALDH1A1 3422/4885MAPK1 1186/4885L3MBTL1 1778/4885
US-20150105317-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 ALDH1A1 3285/4885MAPK1 1090/4885L3MBTL1 1526/4885
US-20200087375-A1 GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES GPR119, IAPP, INSR ALDH1A1 4450/4885MAPK1 2541/4885L3MBTL1 1750/4885
US-20160251407-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 ALDH1A1 3459/4885MAPK1 1013/4885L3MBTL1 1356/4885
US-11041009-B2 Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes GPR119, IAPP, INSR ALDH1A1 4450/4885MAPK1 2541/4885L3MBTL1 1750/4885
US-20240424109-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES GPR119, INSR, IAPP ALDH1A1 4123/4885MAPK1 2453/4885L3MBTL1 1842/4885
US-20160303244-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 ALDH1A1 3285/4885MAPK1 1090/4885L3MBTL1 1526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.